Brief: Pharmaust Says Motor Neurone Disease And COVID-19 Phase 1 Monepantel Clinical Trials On-Track
17/11/2021 01:35
Nov 17 (Reuters) - Pharmaust Ltd PAA.AX :
* MOTOR NEURONE DISEASE AND COVID-19 PHASE 1 MONEPANTEL
CLINICAL
TRIALS ON-TRACK
Source text for Eikon: ID:nASX6cfSH3
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO